Navigation Links
Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
Date:6/15/2009

ilable from Velox (www.velox.com), the firm's current distributor of granules. In Asia the products will be made available directly from Arkema Japan (www.arkema.co.jp).

About OPM
Founded in March 2000, OPM has rapidly become an industry leader in the ultra-high performance thermoplastic polymers market. The firm's versatile OXPEKK® polymers are currently being used in medical, space and defense, semiconductor and industrial markets worldwide. OPM is ISO 9001:2000 and ISO 13485:2003 registered. For additional information, please visit www.oxfordpm.com. In February 2009 OPM was acquired by Arkema.

About Arkema
A global chemical company and France's leading chemicals producer, Arkema consists of three strategically related businesses: Vinyl Products, Industrial Chemicals, and Performance Products. Arkema reported sales of 5.7 billion euros in 2007. Arkema has 15,200 employees across over 40 countries and six research centers located in France, the United States and Japan. With internationally recognized brands, Arkema holds leadership positions in its principal markets.
www.arkema.com

# # #

Read the full story at http://www.prweb.com/releases/2009/06/prweb2530604.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
2. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
3. Bavarian Nordics Case Against Oxford BioMedica
4. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
5. Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.
6. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
7. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
8. Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer
9. Oxford Finance Corporation and GE Healthcare Financial Services Reaffirm Commitment to Biotech Sector in Europe
10. Oxford Genome Sciences Appoints Chris Hibberd to its Board of Directors
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Oxford Performance Materials Introduces OXPEKK PermettaTM High Performance Polymer Films
(Date:12/24/2014)... 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... Clinical Trial Application (CTA) with the United ... seeking regulatory approval to initiate clinical trials for the ... Contingent on the Company receiving CTA regulatory approval, ... to assess the safety, tolerability and dose escalation of ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... , Dec. 22, 2014 GenomeDx Biosciences today ... Prostate Cancer Classifier, a genomic test for prostate cancer, ... high-risk men managed by radical prostatectomy without adjuvant therapy. ... is relatively uncommon, using tumor genomics to identify these ... disease is an important advance. The study has been ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations ... estate, has further expanded its global reach with the ... Western Australia, reports Mylinda Vick, CCIM, Chairman of the ... / ACORPP (Australian Corporate Property and Projects) , is ... services to a wide range of clients in the ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... CALGARY, May 22 /PRNewswire-FirstCall/ - Oncolytics Biotech ... has,successfully transferred cGMP production for REOLYSIN(R) at ... Division of Sigma-Aldrich Corporation.,This follows the successful ... announced,by the Company last year., Yields ...
... AMSTERDAM, The Netherlands, May 22 Amsterdam,Molecular ... field of human gene,therapy, today announced that ... in Rome, Italy, to their advanced small ... of Duchenne,muscular dystrophy (DMD). The combination with ...
... SOUTH SAN FRANCISCO, Calif., May 21 Exelixis,Inc. (Nasdaq: ... and,analyst briefing in conjunction with the 44th Annual Meeting of ... 8:00 p.m. CT,on Monday, June 2, 2008., Participants:, ... Officer -- Michael M. Morrissey, PhD, President of Research ...
Cached Biology Technology:Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 2Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R) 3AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 2AMT Accesses Technology for Treatment of Duchenne Muscular Dystrophy 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 2Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 3Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing 4
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... world,s subspecies of tigers are now extinct. A new study ... a result of human activities, particularly the conversion of natural ... The study, conducted by Virginia Tech and World Wildlife ... investigate the use of different land cover types not ...
... February 29, 2012 A revealing study published in ... epilepsy is not faring well in social media. Kate McNeil ... from Twitter to provide a snapshot of how epilepsy is ... platform launched in 2006, allows its users to communicate through ...
... Wednesday, Feb. 29, 2012, Cleveland: Cleveland Clinic Children,s Hospital ... can be used to help identify children who are ... is designed to confirm the predictive value of established ... that have been completed. Thomas Frazier, Ph.D., of ...
Cached Biology News:Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 2Nowhere to hide: Study finds future of Sumatran tigers threatened by human disturbances 3Is Twitter reinforcing negative perceptions of epilepsy? 2Cleveland Clinic Children's Hospital launches study to genetically test for autism 2
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
Normal canine serum collected from healthy normal canines....
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
Biology Products: